Skip Navigation



BJA Advance Access published online on May 3, 2007
British Journal of Anaesthesia, doi:10.1093/bja/aem101
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
98/6/792    most recent
aem101v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wang, L. Z.
Right arrow Articles by Yao, K. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, L. Z.
Right arrow Articles by Yao, K. Z.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Board of Management and Trustees of the British Journal of Anaesthesia 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Effects of intrathecal and i.v. small-dose sufentanil on the median effective dose of intrathecal bupivacaine for Caesarean section

L. Z. Wang*, Y. F. Zhang, B. L. Tang and K. Z. Yao

Department of Anesthesiology, Jiaxing Maternity and Child Care Hospital, Jiaxing Municipal Sanyi Hospital, Jiaxing 314000, Zhejiang Province, China

* Corresponding author. E-mail: jxlzw{at}56.com

Background: Spinal anaesthesia with bupivacaine combined with sufentanil has been widely used for Caesarean section. However, the main site of action (spinal vs central) of intrathecal (IT) sufentanil is controversial. The aim of this study was to examine the predominant mechanism of action of IT, small-dose sufentanil when added to bupivacaine for Caesarean section, by comparing the effects of IT and i.v. sufentanil 2.5 µg on the median effective dose (ED50) of bupivacaine.

Methods: Ninety parturients undergoing elective Caesarean section with a combined spinal–epidural technique were enrolled into this prospective, double-blind, up-down sequential allocation study. According to the up-down sequential allocation, parturients received varying doses of bupivacaine alone (C group) or co-administered with i.v. sufentanil 2.5 µg group (IVS group; n = 30) or IT sufentanil 2.5 µg group (ITS group; n = 30). The possible maternal or neonatal adverse effects were also recorded.

Results: The ED50 of bupivacaine was 6.3 mg (95% CI 6.2–6.5) in the C group, 5.2 mg (95% CI 5.1–5.4) in the IVS group, and 3.0 mg (95% CI 2.9–3.1) in the ITS group. The ED50 in the ITS group was significantly lower as compared with the other two groups (P<0.0005). With the exception of pruritus that exclusively occurred in the ITS group (P = 0.011, compared with the other two groups), no significant differences among groups were observed regarding the frequencies of the maternal or neonatal adverse effects.

Conclusions: Compared with an equal dose of sufentanil i.v., intrathecally administered sufentanil 2.5 µg has a significant local anaesthetic-sparing effect via a predominantly spinal mechanism for Caesarean section.

Keywords: anaesthesia, obstetric; anaesthetic techniques, regional; anaesthetics local, bupivacaine; pharmacology, sufentanil


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.